MY139830A - Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases - Google Patents

Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases

Info

Publication number
MY139830A
MY139830A MYPI20043935A MYPI20043935A MY139830A MY 139830 A MY139830 A MY 139830A MY PI20043935 A MYPI20043935 A MY PI20043935A MY PI20043935 A MYPI20043935 A MY PI20043935A MY 139830 A MY139830 A MY 139830A
Authority
MY
Malaysia
Prior art keywords
disease
diseases
joint
formula
inflammatory
Prior art date
Application number
MYPI20043935A
Inventor
Manfred Dr Schudok
Hans Dr Matter
Armin Dr Hofmeister
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MY139830A publication Critical patent/MY139830A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPOUNDS OF THE FORMULA I(FORMULA I)ARE SUITABLE FOR PRODUCING PHARMACEUTICALS FOR THE PROPYLAXIS AND THERAPY OF DISEASES WHOSE COURSE INVOLVES AN INCREASE IN THE ACTIVITY OF MATRIX@METALLOPROTEINASES. THESE DISEASES INCLUDE DISEASES SUCH AS DEGENERATIVE @JOINT DISEASE, FOR EXAMPLE OSTEOARTHROSES, SPONDYLOSES AND CHONDROLYSIS @FOLLOWING JOINT TRAUMA OR A RELATIVELY LONG PERIOD OF JOINT IMMOBILIZATION @FOLLOWING MENISCUS INJURIES OR PATELLA INJURIES OR LIGAMENT RUPTURES, OR A @DISEASE OF THE CONNECTIVE TISSUE SUCH AS COLLAGENOSES, PERIODONTAL DISEASES, WOUND HEALING DISTURBANCES, OR A CHRONIC DISEASE OF THE LOCOMOTORY APPARATUS SUCH AS INFLAMMATORY, IMMUNOLOGICALLY DETERMINED @OR METABOLISM-DETERMINED ACUTE OR CHRONIC ARTHRITIDES, ARTHROPATHIES, @MYALGIAS OR DISTURBANCES OF BONE METABOLISM, OR AN ULCERATION, ATHEROSCLEROSIS OR STENOSIS OR AN INFLAMMATORY DISEASE OR A CANCER DISEASE, TIMOUR METASTASES FORMATION, CACHEXIA, ANOREXIA OR SEPTIC SHOCK.
MYPI20043935A 2003-09-27 2004-09-25 Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases MY139830A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10344936A DE10344936A1 (en) 2003-09-27 2003-09-27 Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases

Publications (1)

Publication Number Publication Date
MY139830A true MY139830A (en) 2009-10-30

Family

ID=34353126

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20043935A MY139830A (en) 2003-09-27 2004-09-25 Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases

Country Status (24)

Country Link
EP (1) EP1670766B1 (en)
JP (1) JP4861179B2 (en)
KR (1) KR20060086367A (en)
CN (1) CN1856478B (en)
AR (1) AR046165A1 (en)
AT (1) ATE550327T1 (en)
AU (1) AU2004275937A1 (en)
BR (1) BRPI0414594A (en)
CA (1) CA2539731A1 (en)
DE (1) DE10344936A1 (en)
IL (1) IL174040A0 (en)
MA (1) MA28075A1 (en)
ME (1) MEP33008A (en)
MX (1) MXPA06002927A (en)
MY (1) MY139830A (en)
NO (1) NO20061837L (en)
NZ (1) NZ546158A (en)
PE (1) PE20050432A1 (en)
RS (1) RS20060194A (en)
RU (1) RU2335494C2 (en)
TW (1) TW200520755A (en)
UY (1) UY28539A1 (en)
WO (1) WO2005030728A1 (en)
ZA (1) ZA200601501B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004031620A1 (en) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-trifluoromethoxyphenoxybenzene-4'-sulphonic acids, process for their preparation and use in medicaments
DE102004031850A1 (en) * 2004-06-30 2006-01-26 Sanofi-Aventis Deutschland Gmbh Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicaments
DE102005002500A1 (en) * 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuran derivatives as inhibitors of matrix metalloproteinases
DE102005015040A1 (en) * 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituted tetrahydroisoquinolines as MMP inhibitors, process for their preparation and their use as medicament
EP2182810B1 (en) 2007-08-03 2017-11-08 Nucitec S.A. de C.V. Compositions and methods for treatment and prevention of osteoarthritis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201303B (en) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
FR2701480B1 (en) * 1993-02-15 1995-05-24 Sanofi Elf Compounds with a sulfamoyl and amidino group, process for their preparation and pharmaceutical compositions containing them.
DK0861236T4 (en) 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cyclic and heterocyclic N-substituted alpha-amino hydroxamic and carboxylic acids
CA2264045A1 (en) * 1996-08-28 1998-03-05 Randall Stryker Matthews Heterocyclic metalloprotease inhibitors
PL334846A1 (en) * 1997-01-23 2000-03-27 Hoffmann La Roche Sulphamidic inhibitors of metaloproteases
DE10300015A1 (en) * 2003-01-03 2004-07-15 Aventis Pharma Deutschland Gmbh Imino acid derivatives as inhibitors of matrix metal proteinases
DE102004031620A1 (en) * 2004-06-30 2006-02-02 Sanofi-Aventis Deutschland Gmbh 4-trifluoromethoxyphenoxybenzene-4'-sulphonic acids, process for their preparation and use in medicaments

Also Published As

Publication number Publication date
PE20050432A1 (en) 2005-07-21
EP1670766B1 (en) 2012-03-21
CN1856478B (en) 2010-05-26
RU2006114352A (en) 2006-08-27
NZ546158A (en) 2008-11-28
NO20061837L (en) 2006-06-01
UY28539A1 (en) 2005-04-29
EP1670766A1 (en) 2006-06-21
DE10344936A1 (en) 2005-04-21
AU2004275937A1 (en) 2005-04-07
MA28075A1 (en) 2006-08-01
ZA200601501B (en) 2007-04-25
BRPI0414594A (en) 2006-11-07
WO2005030728A1 (en) 2005-04-07
MXPA06002927A (en) 2006-06-14
CA2539731A1 (en) 2005-04-07
JP4861179B2 (en) 2012-01-25
TW200520755A (en) 2005-07-01
AR046165A1 (en) 2005-11-30
KR20060086367A (en) 2006-07-31
RS20060194A (en) 2008-08-07
JP2007506690A (en) 2007-03-22
ATE550327T1 (en) 2012-04-15
RU2335494C2 (en) 2008-10-10
IL174040A0 (en) 2006-08-01
MEP33008A (en) 2010-10-10
CN1856478A (en) 2006-11-01

Similar Documents

Publication Publication Date Title
WO2005073236A3 (en) Thieno-imino acid derivatives for use as matrix metalloproteinase inhibitors
DE60313624D1 (en) DERIVATIVES OF HETEROARYLNITRILE COMPOUNDS
DK1194425T3 (en) Substituted benzimidazoles
RS20050104A (en) Indole or benzimidazole derivatives for modulating ikb kinase
WO2001019776A3 (en) Novel derivatives of dicarboxylic acid having pharmaceutical properties
EP1583534A4 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
FI950156A (en) Dihydropyratsolopyrroleja
NO20005237D0 (en) Heterocyclic substituted amides used as calpain inhibitors
TNSN05278A1 (en) Inhibitors of phosphatidylinositol 3-kinase
ME01310B (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
BRPI0307351B8 (en) compound, pharmaceutical composition, use of a compound, and, process for preparing a compound
NO20035210D0 (en) 2-anilino-pyrimidine derivatives as cyclin-dependent kinase inhibitors
NO20044763L (en) 1- (aminoalkyl) -3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
DK0600371T3 (en) Guanidine alkyl-1,1-bisphosphonic acid derivatives, process for their preparation and their use
NO20030724D0 (en) Use of derivatives of valproic acid amides and 2 valproic acid amides for the therapy or prevention of pain and / or headache disorders
GEP20084376B (en) Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
MY139830A (en) Bicyclic imino acid derivatives as inhibitors of matrix metalloproteinases
BR0200341A (en) Biphenylsulfonamides useful as matrix metalloprotease inhibitors
WO2008012690A3 (en) Use of 1,2,3-substituted indolizine derivatives, inhibitors of fgfs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
IS6914A (en) 2-thio-substituted imidazole derivatives and their use in the pharmaceutical industry
DE59904875D1 (en) SUBSTITUTED PHENYL-ALKENOYLGUANIDINE, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS MEDICAMENTS OR DIAGNOSTICS AND THE MEDICINES CONTAINING THE SAME
CO5690587A2 (en) BENSOILUREIDOPIRIDIL-PIPERIDIN-Y PIRROLIDIN CARBOXILICO ACID DERIVATIVES, METHOD FOR PRODUCTION AND USE
NZ502366A (en) Aminoethylphenoxyacetic acid derivatives and drugs for pain remission and calculi removal promotion in urinary lithiasis
HK1050141A1 (en) Inhibitor for 20-hete-yielding enzyme
BR0308088A (en) cyclic n-substituted alpha-iminecarboxylic acids for selective inhibition of collagenase